UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF THE

SECURITIES EXCHANGE ACT OF 1934

For the month of ~~May~~June 2026

Commission File Number 001-37652

Biodexa Pharmaceuticals PLC

(Translation of registrant’s name into English)

1 Caspian Point,

Caspian Way

Cardiff, CF10 4DQ, United Kingdom

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F x Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

EXPLANATORY NOTE

On ~~May~~June 1417, 2026, Biodexa ~~Pharmaceuticals~~ Pharmaceuticals PLC (the “Company”) ~~posted~~announced that its Annual ~~Report for the year ended December 31, 2025 (the “Annual Report”) and distributed a Notice of Annual~~ General Meeting ~~(the~~on ~~“AGM~~June ~~Notice”)~~17, ~~and~~2026 ~~letter~~was toadjourned ~~shareholders~~due ~~(the “Shareholder Letter”)~~ to ~~its~~ ~~shareholders.~~lack ~~The Company has also disseminated to its (i) holders~~ of ~~ordinary shares, nominal value £0.000001 per share, a~~ proxy form for the Annual General Meeting (the “Ordinary Shares AGM Proxy Form”) and (ii) holders of American Depositary Shares, a proxy form for the Annual General Meeting (the “ADS AGM Proxy Form”)quorum.

The ~~Company announced that its~~ Annual General Meeting has isbeen re-scheduled to take place on June 1730, 2026 at 11:00 a.m. (London time) at the Company’s registered office at 1 Caspian Point, Caspian Way, Cardiff, Wales, CF10 4DQ. A copy of the press release is furnished hereto as Exhibit 99.1.

A copy of the Annual Report, AGM Notice, Letter to Shareholders, Ordinary Shares AGM Proxy Form and ADS AGM Proxy Form are furnished hereto as Exhibits 99.2, 99.3, 99.4, 99.5 and 99.6, respectively.

The information in this Form 6-K and the exhibits attached thereto is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

SUBMITTED HEREWITH

Attached to the Registrant’s Form 6-K filing for the month of ~~May~~June 2026 is:

Exhibit No.		Description
99.1		Press Release
99.2		Annual Report for the year ended December 31, 2025
99.3		Notice of Annual General Meeting
99.4		Letter to Shareholders
99.5		Annual General Meeting Form of Proxy (Holders of Ordinary Shares)
99.6		Annual General Meeting Form of Proxy (Holders of American Depositary Shares)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Biodexa Pharmaceuticals PLC
Date: May 14, 2026	By:	/s/ Stephen Stamp
Date: June 17, 2026	By:	/s/ Stephen Stamp
		Stephen Stamp
		Chief Executive Officer

Filing Compare · Biodexa Pharmaceuticals Plc